NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 6 June 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Radha Todd (Chair) Present for all items
2. Richard Ballerand Items 1.1 to 5.1.3
3. Dr Craig Buckley Items 1.1 to 4.2.2
4. Dr Andrew Champion Present for all items
5. Dr Patrick De Barr Present for all items
6. Ana Duarte Present for all items
7. Dr Steve Edwards Items 5.1 to 5.2.2
8. Mohamad Farhat Present for all items
9. Dr Fiona MacPherson Smith Items 5.1 to 5.2.2
10. Professor G.J. Melendez-Torres Present for all items
11. Hugo Pedder Present for all items
12. Becky Pennington Present for all items
13. Dominic Pivonka Present for all items
14. Dr Mohit Sharma Present for all items
15. Alan Thomas Present for all items
16. Jaqueline Tomlinson Present for all items
17. Min Ven Teo Present for all items
18. Steven Lloyd Items 1.1 to 4.2.2
19. Stella O’Brien Items 1.1 to 4.2.2

NICE staff (key players) present

Janet Robertson, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Zoe Charles, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ewa Rupniewska, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Janet Boadu, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Isaac Mackenzie, British Medical Journal – Technology Assessment Group

Items 1.1 to 4.2

Alexander Allen, British Medical Journal – Technology Assessment Group Items 1.1 to 4.2

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Mirre Sholte, Kleijnen Systematic Reviews Ltd Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England

Items 1.1 to 4.2.2

Iain McNeish, Professor of Oncology, clinical expert nominated by AstraZeneca

Items 1.1 to 4.2

Rebecca Kristeleit, Consultant Medical Oncologist, clinical expert nominated by British Gynaecological Cancer Society Items 1.1 to 4.2

Rachel Downing, Head of Policy & Campaigns, patient expert nominated by Target Ovarian Cancer Items 1.1 to 4.2

Anna Hudson, Head of Support Services, patient expert nominated by Ovacome

Items 1.1 to 4.2

Michael Cummings, Consultant, Diabetes and Endocrinology, clinical expert nominated by Eli Lilly Items 5.1 to 5.1.3

Stephen Bain, Professor of Medicine (Diabetes), clinical expert nominated by NovoNordisk and the Association of British Clinical Diabetologists Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Dr Radha Todd welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr David Maudgil, Dr James Fotheringham, Dr Justin Daniels, Dr Peter Baker-Gulliver and Dr Pratheeban Nambyiah.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 3 May 2023.

### Appraisal of Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] [ID4066]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10978).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Mohit Sharma (clinical), Richard Ballerand (lay), and Ana Duarte (cost).
     4. The committee discussed confidential information submitted for this item.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10978>.

### Appraisal of Tirzepatide for treating type 2 diabetes [ID3938]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Eli Lilly & Company.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10835).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Alan Thomas (lay), Fiona MacPherson Smith (clinical), and Min Ven Teo (cost).
  2. Part 2 – Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10835>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 4 July 2023 and will start promptly at 10:00am.